Download Files:

ONO-3403

Products Details

Product Description

– ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors[1][2][3][4].

Web ID

– HY-123542

Shipping

– Room temperature

Molecular Formula

– C26H31N3O8S

References

– [1]Tumurkhuu G, et al. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 2011;17(1):97-105.|[2]Hiwasa T, et al. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 1998;126(2):221-225.|[3]Ohkoshi M, et al. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res. 2002;22(2A):821-823.

CAS Number

– 181586-07-2

Molecular Weight

– 545.60

SMILES

– O=C(C1=CC=C(C=C1)/C=C(C(N(CC=C)CC(OCC)=O)=O)C)OC2=CC=C(C=C2)C(N)=N.CS(=O)(O)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– Apoptosis;Ser/Thr Protease

Pathway

– Apoptosis;Metabolic Enzyme/Protease

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.